Condition: Hypercholesterolaemia · Sponsor: Novartis Pharmaceuticals
This is a multicenter, randomized, double-blind, factorial design Phase 2 study to evaluate the pharmacodynamics, safety and tolerability of a combination of QCZ484 and inclisiran compared to QCZ484, inclisiran, and placebo in participants with hypertension and concomitant hypercholesterolemia.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals
Always discuss trial participation with your own doctor first.
| G and L Research LLC | Foley, Alabama, United States | Recruiting |
| The Center for Clinical Trials | Saraland, Alabama, United States | Recruiting |
| Clinical Trials Research | Lincoln, California, United States | Recruiting |
| Downtown L A Research Center Inc | Los Angeles, California, United States | Recruiting |
| Valley Clinical Trials | Northridge, California, United States | Recruiting |
| Flourish Medical Clinical Trials | Boca Raton, Florida, United States | Recruiting |
| ALL Medical Research LLC | Cooper City, Florida, United States | Recruiting |
| AMR Miami | Coral Gables, Florida, United States | Recruiting |
| Universal Axon Clinical Research | Doral, Florida, United States | Recruiting |
| East Coast Institute for Research | Jacksonville, Florida, United States | Recruiting |
| Entrust Clinical Research | Miami, Florida, United States | Recruiting |
| Inpatient Research Clinical LLC | Miami Lakes, Florida, United States | Recruiting |
+ 14 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07610278